Common adverse events included rash and hypomagnesemia. Eli Lilly will present additional safety and efficacy data on the candidate from the study at the annual meeting of the American Society of Clinical Oncology (ASCO). The company expects to file for approval by the end of 2014. The company has full global development and commercialization rights to necitumumab. Earlier, Eli Lilly had a collaboration with Bristol-Myers Squibb BMY for necitumumab in North America and Japan. However, Bristol-Myers terminated the collaboration in late 2012. Our Take We believe Eli Lilly's pipeline must deliver to counter its dwindling revenues due to genericization of key products like Zyprexa, Cymbalta and Evista. We are also pleased to see Lilly pursuing small acquisitions and in-licensing deals to boost its pipeline. The approval of necitumumab would be a major positive for Eli Lilly.